The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).
about
Concise Review: Epigenetic Regulation of Myogenesis in Health and DiseaseRhabdomyosarcoma: current challenges and their implications for developing therapies.MicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in embryonal rhabdomyosarcoma.EZH2 suppresses the nucleotide excision repair in nasopharyngeal carcinoma by silencing XPA gene.Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology GroupHelicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma.Alveolar rhabdomyosarcoma: morphoproteomics and personalized tumor graft testing further define the biology of PAX3-FKHR(FOXO1) subtype and provide targeted therapeutic options.Roles of enhancer of zeste homolog 2: from skeletal muscle differentiation to rhabdomyosarcoma carcinogenesis.New insights into signalling-pathway alterations in rhabdomyosarcoma.P/CAF mediates PAX3-FOXO1-dependent oncogenesis in alveolar rhabdomyosarcoma.Potential roles of EZH2, Bmi-1 and miR-203 in cell proliferation and invasion in hepatocellular carcinoma cell line Hep3B.Recent advances in SCF ubiquitin ligase complex: Clinical implicationsTargeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatmentFBXO32 Targets c-Myc for Proteasomal Degradation and Inhibits c-Myc Activity.Praja1 E3 ubiquitin ligase promotes skeletal myogenesis through degradation of EZH2 upon p38α activation.The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells.High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas.Hedgehog-driven myogenic tumors recapitulate skeletal muscle cellular heterogeneity.12-O-tetradecanoylphorbol-13-acetate and EZH2 inhibition: A novel approach for promoting myogenic differentiation in embryonal rhabdomyosarcoma cells.Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.Pyrazole-based inhibitors of enhancer of zeste homologue 2 induce apoptosis and autophagy in cancer cells.Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics.3F-Box protein 32 degrades ataxia telangiectasia and Rad3-related and regulates DNA damage response induced by gemcitabine in pancreatic cancer.High expression of EZH2 as a marker for the differential diagnosis of malignant and benign myogenic tumorsEZH2 contributes to 5-FU resistance in gastric cancer by epigenetically suppressing FBXO32 expressionPannexin 1 inhibits rhabdomyosarcoma progression through a mechanism independent of its canonical channel function
P2860
Q28072184-E6C16619-6C7D-42F7-A8DF-1578FA1AECD9Q34400242-B340983A-2ACE-4802-AE99-4BBC2CD8BCDDQ35922940-FA53AE1B-6B3E-4D9E-87A6-310684D9D22FQ36037967-44995AAC-3098-4240-8EA9-7A7DDED3AA10Q36175120-31E74F74-A0D1-4A5F-8E2E-FEAD04B447F9Q37395824-018B0164-B135-41BD-AAAC-6BDAA8E18D48Q37564708-1FDB8833-CFB8-4E14-A496-DA433F370D04Q38185265-B6C441FC-5983-4645-9DBC-F8CB2B34899FQ38248375-E5828DF9-0012-43C7-85D8-A51729C82173Q38740103-AF607ACF-A0A1-495B-8A97-03AF4E67B358Q38808091-92EEDD07-AB49-417E-86B2-CDFF76E9802DQ38828721-E77BE4A4-DF0F-463C-9343-04A9EBBE6695Q40014635-8E8145C2-981B-49DD-B5F8-F429A667A24FQ40972142-405623FE-3656-47CC-B86B-72379A54972CQ42282686-FB305C90-199D-46A6-81F6-921C62DB1B20Q42366629-E47C11D9-1A1E-4108-BB07-C2F4598DBA7CQ42398063-64A1EDBC-AD7F-4715-A2F9-F99D052999F3Q43080027-6640845F-2AB1-43D5-919B-0EE436E9EB81Q48102348-8A220AA2-4A71-4170-BE42-F7BB76E6F0DCQ50324483-2F8651F7-EB14-4F4E-B205-BD4F8ABB3477Q52568730-3475BF6C-093A-4C27-9234-1AE64BE09A9DQ53419446-53F19A8C-1FFC-4866-AC53-92AD848AEF72Q54977999-9221B52B-4F87-4AAE-B31B-104C65E6E803Q58771183-677B15A4-494E-4350-8A75-AB90B26A78D0Q59125701-0836EA46-FB50-48EF-A9FA-A535DE21F633Q59134675-CE8708FF-F329-4D87-8103-89D1BD917C82
P2860
The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
The Polycomb group (PcG) prote ...... ssing FBXO32 (Atrogin1/MAFbx).
@en
The Polycomb group
@nl
type
label
The Polycomb group (PcG) prote ...... ssing FBXO32 (Atrogin1/MAFbx).
@en
The Polycomb group
@nl
prefLabel
The Polycomb group (PcG) prote ...... ssing FBXO32 (Atrogin1/MAFbx).
@en
The Polycomb group
@nl
P2093
P2860
P50
P356
P1433
P1476
The Polycomb group (PcG) prote ...... essing FBXO32 (Atrogin1/MAFbx)
@en
P2093
A Dall'Agnese
E Carcarino
F Locatelli
G Bracaglia
I Screpanti
M De Salvo
P2860
P2888
P304
P356
10.1038/ONC.2013.471
P407
P50
P577
2013-11-11T00:00:00Z